Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 8-K - Current report Filed: 2018-08-07 AccNo: 0001104659-18-050163 Size: 61 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain...
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 8-K - Current report Filed: 2018-08-07 AccNo: 0001104659-18-050163 Size: 61 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain...
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ CT ORDER - Confidential treatment order Filed: 2018-08-03 AccNo: 9999999997-18-007156 Size: 11 KB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2018-08-06 AccNo: 0001615774-18-007607 Size: 102 KB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-08-03 AccNo: 0001193125-18-236943 Size: 197 KB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2018-07-31,Director,BURGESS DANIEL D ,买入,36000普通股, $2.75
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2018-07-31,Director,Talbot George Harrison ,买入,14500普通股, $2.75
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 8-K - Current report Filed: 2018-08-01 AccNo: 0001104659-18-048818 Size: 332 KBItem 1.01: Entry into a Material Definitive AgreementItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ D - Notice of Exempt Offering of Securities Filed: 2018-07-27 AccNo: 0001641640-18-000001 Size: 16 KB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2018-07-27 AccNo: 0001047469-18-005256 Size: 1 MB 网页链接